Verpasep caltespen API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Verpasep caltespen API 295371-00-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Verpasep caltespen. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Verpasep caltespen
- Synonyms:
- BCG65-E7 , Heat-shock protein HSP 65 (Mycobacterium BCG) fusion protein with transcription factor E7 (human papillomavirus 16) , HPV 16 E7/HSP65 vaccine , HPV E7 Peptide Epitope Vaccine , HspE7 , Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7 , Verpasep caltespen
- Cas Number:
- 295371-00-5
- DrugBank number:
- DB04959
- Unique Ingredient Identifier:
- Z7T0JI2E2I
General Description:
Verpasep caltespen, identified by CAS number 295371-00-5, is a notable compound with significant therapeutic applications. HspE7 is a recombinant chimeric protein composed of the heat shock protein 65 (Hsp65) from _Mycobacterium bovis_, and the human papilloma viral (HPV) protein E7. Hsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers. E7 protein is involved in carcinogenesis of anal and cervical tumors, and represents a tumor antigen that may be specifically targeted by lymphocytes. It is being developed by StressGen Biotechnologies Corp.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in anal dysplasia, cervical dysplasia/cancer, genital warts, HIV infection, infectious and parasitic disease (unspecified), pediatric indications, warts, and viral infection. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Verpasep caltespen functions by: HspE7 works by efficiently delivering the E7 antigen to dendritic cells, which have a natural affinity for Hsp. Dendritic cells are known to be the most potent cells in the body for triggering immune responses. Coupling E7 to Hsp takes advantage of the Hsp receptors that dendritic cells express on their surface to introduce E7, as part of a larger fusion protein, into the dendritic cells. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Verpasep caltespen is a type of Anti-HIV
The Anti-HIV category of pharmaceutical APIs comprises a range of active pharmaceutical ingredients (APIs) specifically designed to combat the human immunodeficiency virus (HIV). These APIs play a critical role in the development and production of antiretroviral drugs, which are used to treat HIV infections and prevent the progression to acquired immunodeficiency syndrome (AIDS).
Anti-HIV APIs work by targeting various stages of the HIV life cycle, inhibiting viral replication and reducing the viral load in the body. Some commonly used APIs in this category include nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (INIs).
NRTIs, such as tenofovir and emtricitabine, act by blocking the reverse transcriptase enzyme, an essential component in the replication of the virus. NNRTIs, such as efavirenz and nevirapine, bind to the reverse transcriptase enzyme, preventing its proper functioning. PIs, like ritonavir and atazanavir, inhibit the protease enzyme, crucial for viral maturation and assembly. INIs, such as raltegravir and dolutegravir, target the integrase enzyme, impeding viral integration into the host's DNA.
These APIs are carefully synthesized and undergo rigorous quality testing to ensure their safety, efficacy, and compliance with regulatory standards. Pharmaceutical companies utilize these APIs as key building blocks to formulate antiretroviral medications, which are then prescribed to individuals living with HIV/AIDS worldwide.
Overall, the Anti-HIV API category plays a vital role in the ongoing battle against HIV/AIDS, offering effective treatment options and improved quality of life for patients affected by this challenging condition.
